Eliquis Tablet, Film Coated
Product Images NDC 55154-0613

10 FDA label images from Cardinal Health 107, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Eliquis (NDC 55154-0613). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aristotle Major Bleeding Forest Plot (Aristotle Major Bleeding Forest Plot)

Aristotle Major Bleeding Forest Plot (Aristotle Major Bleeding Forest Plot)
A forest plot comparing apixaban and warfarin across multiple patient subgroups. It displays hazard ratios with 95% confidence intervals, showing events per number of patients and percentage per year. Subgroups include age, sex, weight, prior stroke or TIA, diabetes mellitus, CHADS2 score, creatinine clearance, geographic region, and aspirin use. The x-axis indicates relative risk favoring apixaban or warfarin.*
FDA Label Image

Apixaban Chemical Structure (Apixaban Struct)

Apixaban Chemical Structure (Apixaban Struct)
Chemical structure of apixaban, the active ingredient in ELIQUIS. The diagram shows the molecular arrangement including rings and functional groups characteristic of this anticoagulant drug.*
FDA Label Image

Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)

Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)
A forest plot chart showing the fold change and 90% confidence intervals in pharmacokinetic parameters (Cmax and AUC) of ELIQUIS (apixaban) when interacting with various drugs. The chart lists combined P-gp and strong CYP3A4 inhibitors (ketoconazole 400 mg, clarithromycin 500 mg), other CYP3A4 and P-gp inhibitors (diltiazem 360 mg, naproxen 500 mg), and a combined P-gp and strong CYP3A4 inducer (rifampin 600 mg). The x-axis represents change relative to reference with values ranging from 0.5 to 2.0.*
FDA Label Image

O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)

O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)
A clinical pharmacokinetic chart displaying fold changes with 90% confidence intervals for Cmax and AUC of apixaban in various population subgroups, including different levels of renal impairment, age groups, body weights, and hepatic impairment. The chart also includes associated dosing recommendations for each subgroup, mostly indicating no dose adjustment except for moderate hepatic impairment where no dosing recommendation is provided.*
FDA Label Image

Aristotle Kaplan-meier Curve (Eliquis Km Fig4)

Aristotle Kaplan-meier Curve (Eliquis Km Fig4)
A Kaplan-Meier curve displaying the proportion of subjects experiencing stroke or systemic embolism over 36 months, comparing ELIQUIS (apixaban) and Warfarin. The graph includes event counts, number of subjects at risk at select time points, and statistical measures (P-value 0.0114; hazard ratio 0.79).*
FDA Label Image

Aristotle Forest Plot (Eliquis Clin Forest Fig5)

Aristotle Forest Plot (Eliquis Clin Forest Fig5)
A forest plot comparing the number of events and hazard ratios between apixaban and warfarin treatments across various patient subgroups. The horizontal axis measures hazard ratios with markers indicating relative risk and 95% confidence intervals for each subgroup, illustrating the comparative effectiveness of apixaban versus warfarin in terms of event rates.*
FDA Label Image

2.5mg Bag Label (C6b2240a A9d6 4dd9 9bc4 B42dc90c0d2f 03)

2.5mg Bag Label (C6b2240a A9d6 4dd9 9bc4 B42dc90c0d2f 03)
ELIQUIS tablets 2.5 mg (apixaban) unit dose packaging label. The label shows each tablet contains 2.5 mg apixaban, with a quantity of 10 tablets. It includes storage instructions, dosage warning, and notes that the package is not child resistant and intended for institutional use only. The label lists Bristol-Myers Squibb Company and Pfizer Inc as marketers, and Cardinal Health as distributor.*
FDA Label Image

2.5mg Bottle Label (C6b2240a A9d6 4dd9 9bc4 B42dc90c0d2f 02)

2.5mg Bottle Label (C6b2240a A9d6 4dd9 9bc4 B42dc90c0d2f 02)
Label for ELIQUIS (apixaban) tablets, 2.5 mg strength. The label indicates each tablet contains 2.5 mg apixaban, marked as Rx only, with a warning to keep out of reach of children. It includes storage instructions, manufacturer details (Pfizer Inc and Bristol-Myers Squibb Company), and barcode information. The package contains approximately 4140 tablets, distributed by Cardinal Health 107, LLC.*
FDA Label Image

5mg Bag Label (C6b2240a A9d6 4dd9 9bc4 B42dc90c0d2f 01)

5mg Bag Label (C6b2240a A9d6 4dd9 9bc4 B42dc90c0d2f 01)
This is a drug facts text panel for ELIQUIS 5 mg tablets containing apixaban. The panel includes dosage information, storage instructions, warnings about child resistance and intended institutional use, marketing and distribution details by Bristol-Myers Squibb, Pfizer Inc, and Cardinal Health. It specifies the product is RX only and provides storage temperature ranges.*
FDA Label Image

5mg Bottle Label (C6b2240a A9d6 4dd9 9bc4 B42dc90c0d2f 00)

5mg Bottle Label (C6b2240a A9d6 4dd9 9bc4 B42dc90c0d2f 00)
Label for ELIQUIS 5 mg (apixaban) tablets. The prescription oral film-coated tablets contain 5 mg of apixaban each. The label includes storage instructions, barcode, and warnings to keep out of reach of children. Labeler information shows Cardinal Health 107, LLC and Pfizer Inc. The container holds approximately 2040 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.